Literature DB >> 23458608

Notch inhibitors for cancer treatment.

Ingrid Espinoza1, Lucio Miele.   

Abstract

Notch signaling is an evolutionarily conserved cell signaling pathway involved in cell fate during development, stem cell renewal and differentiation in postnatal tissues. Roles for Notch in carcinogenesis, in the biology of cancer stem cells and tumor angiogenesis have been reported. These features identify Notch as a potential therapeutic target in oncology. Based on the molecular structure of Notch receptor, Notch ligands and Notch activators, a set of Notch pathway inhibitors have been developed. Most of these inhibitors had shown anti-tumor effects in preclinical studies. At the same time, the combinatorial effect of these inhibitors with current chemotherapeutical drugs is still under study in different clinical trials. In this review, we describe the basics of Notch signaling and the role of Notch in normal and cancer stem cells as a logic way to develop different Notch inhibitors and their current stage of progress for cancer patient's treatment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23458608      PMCID: PMC3732476          DOI: 10.1016/j.pharmthera.2013.02.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  259 in total

1.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling.

Authors:  Qinghua Zeng; Shenglin Li; Douglas B Chepeha; Thomas J Giordano; Jong Li; Honglai Zhang; Peter J Polverini; Jacques Nor; Jan Kitajewski; Cun-Yu Wang
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

2.  The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog.

Authors:  C Oberg; J Li; A Pauley; E Wolf; M Gurney; U Lendahl
Journal:  J Biol Chem       Date:  2001-07-18       Impact factor: 5.157

3.  Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase.

Authors:  L Qiu; C Joazeiro; N Fang; H Y Wang; C Elly; Y Altman; D Fang; T Hunter; Y C Liu
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

4.  p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.

Authors:  Pasquale Sansone; Gianluca Storci; Catia Giovannini; Silvia Pandolfi; Simona Pianetti; Mario Taffurelli; Donatella Santini; Claudio Ceccarelli; Pasquale Chieco; Massimiliano Bonafé
Journal:  Stem Cells       Date:  2006-12-07       Impact factor: 6.277

5.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.

Authors:  Franziska Jundt; Ioannis Anagnostopoulos; Reinhold Förster; Stephan Mathas; Harald Stein; Bernd Dörken
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa.

Authors:  F Oswald; S Liptay; G Adler; R M Schmid
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

7.  Feed-back mechanisms affecting Notch activation at the dorsoventral boundary in the Drosophila wing.

Authors:  J F de Celis; S Bray
Journal:  Development       Date:  1997-09       Impact factor: 6.868

8.  The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase.

Authors:  Emmanuelle Six; Delphine Ndiaye; Yacine Laabi; Christel Brou; Neetu Gupta-Rossi; Alain Israel; Frederique Logeat
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-06       Impact factor: 11.205

9.  Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells.

Authors:  Ji Young Jang; Min Kyoung Kim; Yoon Kyung Jeon; Yoon Ki Joung; Ki Dong Park; Chul Woo Kim
Journal:  Exp Mol Med       Date:  2012-04-30       Impact factor: 8.718

10.  Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Authors:  Leopoldo Luistro; Wei He; Melissa Smith; Kathryn Packman; Maria Vilenchik; Daisy Carvajal; John Roberts; James Cai; Windy Berkofsky-Fessler; Holly Hilton; Michael Linn; Alexander Flohr; Roland Jakob-Røtne; Helmut Jacobsen; Kelli Glenn; David Heimbrook; John F Boylan
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

View more
  119 in total

1.  Targeting Notch Signaling in Colorectal Cancer.

Authors:  Suman Suman; Trinath P Das; Murali K Ankem; Chendil Damodaran
Journal:  Curr Colorectal Cancer Rep       Date:  2014-12-01

2.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Authors:  Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

3.  Notch Signaling Pathway in Pancreatic Cancer Progression.

Authors:  Jia Ma; Jun Xia; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Pancreat Disord Ther       Date:  2013-05-30

4.  Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt.

Authors:  Wanhu Zhu; Qing Liang; Xu Yang; Yan Yu; Xiaoying Shen; Guangchun Sun
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

5.  p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via MAML1.

Authors:  Jieun Yun; Ingrid Espinoza; Antonio Pannuti; Damian Romero; Luis Martinez; Mary Caskey; Adina Stanculescu; Maurizio Bocchetta; Paola Rizzo; Vimla Band; Hamid Band; Hwan Mook Kim; Song-Kyu Park; Keon Wook Kang; Maria Laura Avantaggiati; Christian R Gomez; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

6.  Wnt/Beta-Catenin Signal Inhibitor HC-1 Sensitizes Oral Squamous Cell Carcinoma Cells to 5-Fluorouracil through Reduction of CD44-Positive Population.

Authors:  Satoshi Yokogi; Toshiaki Tsubota; Keita Kanki; Junya Azumi; Noriko Itaba; Hiroyuki Oka; Minoru Morimoto; Kazuo Ryoke; Goshi Shiota
Journal:  Yonago Acta Med       Date:  2016-06-29       Impact factor: 1.641

7.  A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.

Authors:  Dan-Dan Li; Chang-Hao Zhao; Huai-Wei Ding; Qiong Wu; Tian-Shu Ren; Jian Wang; Cong-Qin Chen; Qing-Chun Zhao
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

8.  Colon cancer stem cells: Potential target for the treatment of colorectal cancer.

Authors:  Riya Gupta; Lokesh Kumar Bhatt; Thomas P Johnston; Kedar S Prabhavalkar
Journal:  Cancer Biol Ther       Date:  2019-05-03       Impact factor: 4.742

9.  Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression.

Authors:  Hidetaka Ohnuki; Kan Jiang; Dunrui Wang; Ombretta Salvucci; Hyeongil Kwak; David Sánchez-Martín; Dragan Maric; Giovanna Tosato
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

Review 10.  Cellular and molecular biology of small cell lung cancer: an overview.

Authors:  Niki Karachaliou; Sara Pilotto; Chiara Lazzari; Emilio Bria; Filippo de Marinis; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.